“ADA 2026 GLP-1 Pipeline: Retatrutide, CagriSema, Orforglipron The next wave of incretin therapies unveiled in New Orleans” (2026) Diabzen, 4(23), pp. 46–47. Available at: https://thediabzen.com/index.php/d/article/view/66 (Accessed: 28 July 2026).